- Home
- EQX vs GH Comparison
EQX vs GH Comparison
Compare EQX & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- GH
- Stock Information
- Founded
- EQX 2007
- GH 2011
- Country
- EQX Canada
- GH United States
- Employees
- EQX N/A
- GH N/A
- Industry
- EQX Precious Metals
- GH Medical Specialities
- Sector
- EQX Basic Materials
- GH Health Care
- Exchange
- EQX Nasdaq
- GH Nasdaq
- Market Cap
- EQX 4.6B
- GH 4.9B
- IPO Year
- EQX N/A
- GH 2018
- Fundamental
- Price
- EQX $6.06
- GH $41.42
- Analyst Decision
- EQX
- GH Strong Buy
- Analyst Count
- EQX 0
- GH 18
- Target Price
- EQX N/A
- GH $55.67
- AVG Volume (30 Days)
- EQX 13.1M
- GH 2.4M
- Earning Date
- EQX 08-13-2025
- GH 07-30-2025
- Dividend Yield
- EQX N/A
- GH N/A
- EPS Growth
- EQX N/A
- GH N/A
- EPS
- EQX 0.64
- GH N/A
- Revenue
- EQX $1,696,526,000.00
- GH $828,849,000.00
- Revenue This Year
- EQX $59.63
- GH $23.36
- Revenue Next Year
- EQX $44.19
- GH $21.43
- P/E Ratio
- EQX $14.93
- GH N/A
- Revenue Growth
- EQX 54.88
- GH 28.74
- 52 Week Low
- EQX $4.48
- GH $20.14
- 52 Week High
- EQX $7.45
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- EQX 42.80
- GH 32.00
- Support Level
- EQX $6.17
- GH $43.25
- Resistance Level
- EQX $6.38
- GH $46.25
- Average True Range (ATR)
- EQX 0.21
- GH 1.91
- MACD
- EQX -0.01
- GH -0.70
- Stochastic Oscillator
- EQX 8.70
- GH 11.25
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.